Abstract: Methods and compositions that provide for the long-term adhesion and slow-release of various bioactive agents on the surface of human skin utilize siloxane bridging agents activated for reaction with the skin surface which bind the bioactive agent to the skin surface. Since the topical agent remains bound to the continuously renewing epidermis, safety is enhanced for many bioactive agents. Slight modifications of the siloxane bridging compounds or bioactive agents allows for more or less adhesion to the skin, controlling the degree of release of the agent. Skin treatments according to the invention can provide enhanced repellency to microorganisms, insect bites, sun, water, poison ivy/oak, and other skin irritants, and other effects such as artificial skin coloring and administration of topical drugs, among others.

Abstract: The present invention provides an infant formula for infants with metabolic disorders in fatty acid catabolism such as medium-chain acyl-CoA dehydrogenase deficiency (MCAD), long-chain acyl-CoA dehydrogenase deficiency (LCAD), short-chain acyl-CoA dehydrogenase deficiency (SCAD), multiple acyl-CoA dehydrogenase deficiency (MADD), Sudden Infant Death Syndrome (SIDS) and failure to thrive syndrome. The present invention also provides an assay for diagnosing children and infants with metabolic disorders such as failure to thrive syndrome; a method for treating failure to thrive syndrome; and a process for normalizing the lipid content of the mitochondrial membrane. In particular, the present invention provides an infant formula containing 90-130 cals/Kg which comprises (a) 2.5-3.5 g/Kg protein; (b) carbohydrate; (c) fat; and (d) .gtoreq.500 mg carnitine, wherein the ratio of carbohydrate to fat is greater than or equal to 60:40.

Abstract: The invention describes an herbal formulation and its use for reducing/alleviating symptoms associated with rheumatoid arthritis, osteoarthritis and reactive arthritis and for reducing the production of proinflammatory cytokines. Foods and beverages containing the herbal formulation are also described.

Abstract: 1-[4-(4'-sulfanilyl)phenyl]urea and its various substituted derivatives can be used to decrease the infectiousness of and reduce the mortality associated with organisms of the genus Leishmania which are responsible for a group of conditions known as Leishmaniasis. This heretofore unrecognized use extends to the known derivatives of ureidodiaminodiphenyl sulfones and includes the novel aryl-ring hydroxylated series of sulfanilylphenylureas of the formula: ##STR1## wherein m and n can be the same or different and may each =0 or 1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6 are the same or different and are selected from the group consisting of hydrogen, hydroxyl, halo, C.sub.1 to C.sub.6 straight or branch chain alkyl, halo alkyl, polyhalo alkyl, alkoxy, cyano, amino, alkanoylamino, alkoxycarbonylamino, carboxy, alkoxycarbonyl, carbamoyl, acyl, R.sup.7, and R.sup.8 are the same or different and are selected from the group consisting of hydrogen, and C.sub.1 to C.sub.

Abstract: A method for the topical treatment of skin affected with acne, rosacea, or a combination thereof. Sodium chloride in a substantially pure form is topically applied to the affected skin by gently gliding the sodium chloride over the affected skin in a manner insufficient to cause abrasion and debridement of the affected skin. A solid block of about 98% to about 100% by weight sodium chloride free of a carrier and/or free of other topical acne-treatment medicaments and/or free of other topical rosacea-treatment medicaments should be used. The applied sodium chloride is left on the skin. Preferably, the affected skin is pre-moistened with water from shaving, bathing, splashing water on the skin, and the like prior to gliding the sodium chloride thereon.

Abstract: The present invention provides methods for treating autoimmune disease in humans by administering to an afflicted host pharmaceutical compositions containing a therapeutically effective amount of a combination of ##STR1## in a weight ratio ranging from about 1:1 to about 1:10 (A:B); wherein R is OH, NH.sub.2, OW, or H;X is H, F, Cl, Br, I, OH, OW, NO.sub.2, or NH.sub.2 ;Y is H, F, Cl, Br, or I;W is ##STR2## or a C.sub.1 to C.sub.12 aliphatic group; Z is an aliphatic or aromatic group of C.sub.1 to C.sub.12 ;X and Y can both vary within the compound; or pharmaceutically acceptable salts thereof.Particularly disclosed herein is a composition comprising a 1 to 4 ratio of the sodium salts of phenylacetylglutamine and phenylacetic acid, formulated in both oral and parenteral forms clinically useful in the treatment of rheumatoid arthritis, lupus erythematosus, vasculitis, insulin dependent diabetes mellitus and multiple sclerosis.

Abstract: A method of treating endotoxic shock in mammals, comprising administering an effective amount of a pharmaceutically acceptable gallium compound. A preferred gallium compound is gallium nitrate.

Abstract: The present invention provides agents for inhibiting production of interleukin-8 and for inhibiting granulocytes activation as well as novel method for curing inflamatory diseases. The agents for inhibiting production of interleukin-8, and for inhibiting granulocytes activation and for curing inflammatory diseases, which contains as an active ingredient, a carbostyril derivative represented by the general formula (I): ##STR1## where R is as described in the specification.

Abstract: In accordance with the present invention, a method and device is provided for administering therapeutically effective doses of the drug azospirone transdermally for treating psychogenic symptomatologies. One embodiment of the present invention comprises an effective amount of solubilized azospirone in a transdermal drug delivery device. By practicing the present invention, constant blood concentrations of azospirone can be maintained over a prolonged period of time, side effects can be minimized with maximal patient compliance.

Abstract: Compounds capable of interacting with the strychnine-insensitive glycine modulatory site of the N-methyl-D-aspartate (NMDA) receptor are active in preventing or reducing dependence on dependence-inducing agents such as morphine, but lack the undesirable side-effects of agents hitherto employed for this purpose.

Abstract: The present invention provides a simple, cheap and efficient cure for the common cold, and comprises a nasal spray of a dilute solution of substantially unchelated zinc ion, especially zinc sulphate and/or zinc chloride.

Abstract: A method of treating emesis in a warm blooded animal by administering an anti-emesis effective amount of a nitric oxide synthase inhibitor and compositions containing the same.

Abstract: Pharmaceutical composition comprising a tetrahydronaphthalene derivative of the formula ##STR1## wherein R.sup.1 is halogen, R.sup.2 is lower-alkoxy-lower-alkylcarbonyloxy, X is C.sub.2 -C.sub.8 -alkylene and A is benzimidazolyl optionally substituted at the N atom by alkyl with 1 to 12 C atoms,and a pyridazodiazepine of the formula ##STR2## wherein R.sup.4 is aralkyl with 1 to 6 C atoms in the alkyl residue and phenyl, which is optionally mono-substituted by halogen, alkoxy with 1 to 6 C atoms or phenyl, as the aryl residue, R.sup.5 and R.sup.6 each independently are hydrogen or alkyl with 1 to 6 C atoms and R.sup.7 and R.sup.8 each are hydrogen or together are an oxo group,in the form of their free bases, their hydrates or their pharmaceutically usable salts for the simultaneous, separate or planned stepwise use in the control or prevention of circulatory disorders, especially hypertension.

Abstract: Racemic or optically active pyrido[1,2-a]pyrazine derivatives of the formula ##STR1## wherein X is N or CH and Y represents one of certain pyrazolo, triazolo, tetrazolo or cyclic imido radicals are useful in the treatment of abuse of and/or addiction to such substances as narcotics, alcohol and nicotine.

Abstract: Cosmetic or pharmaceutical composition for the treatment of hair and of the scalp, obtained by using an aqueous solution containing at least one cationic surface-active agent and/or a quaternized protein, in combination with ionic lipids capable of forming a lipidic lamellar phase.

Abstract: The invention relates to pharmaceutical preparations, containing a specific crystal modification (subsequently called "modification II") of isopropyl-(2-methoxyethyl) 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate (nimodipine) and to a process for its preparation.

Abstract: A method of treating a patient in need of stimulation of hepatocyte mitosis which comprises administering to said patient an effective amount of alanine and/or glutamine.

Abstract: An improved method and composition for promoting hair growth in mammals for treating various forms of alopecia or male pattern baldness comprising the concomitant administration of potassium channel openers, such as minoxidil, cromakalim, pinacidil, or a compound selected frown the classes of s-triazine, thiane-1-oxide, benzopyran and pyridinopyran compounds; and a 5.alpha.-reductase inhibitors, 17.beta.-(N-tert-butylcarbamoyl)-4-aza-5-.alpha.-androst-1-en-3-one. The method comprises administering an effective amount of the potassium channel opener and administering an effective amount of the 17.beta.-(N-tert-butylcarbamoyl)-4-aza-5-.alpha.-androst-1-en-3-one whereby the promotion of hair growth is increase over the sole administration of the potassium channel opener.

Abstract: A composition is disclosed containing nonesterified fatty acids having 14-18 carbon atoms, monoglycerides which are monoesters of glycerol and fatty acids having 14-18 carbon atoms, lysophosphatidylcholine in which the fatty acid moiety has 14-18 carbon atoms and bicarbonate. The compositions can optionally also contain bile salts. These compositions form submicron size colloidal particles and can act as vehicles for transporting orally administered drugs, sources of calories in the form of readily absorbable fats and as particles for topical application to the skin. A method of making these particles is also described.

Abstract: An aqueous cosmetic or dermo-pharmaceutical composition contains, in suspension in the continuous phase, hydrated spheroids of a hydrophilic lipidic substance. The hydrated spheroids have an average particle diameter ranging from 50 to 10,000 .mu.m. A process for the preparation of this composition is described.